Royalty Pharma plcRPRX

Market cap

$22.7B

P/E ratio

	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024
Cash and cash equivalents	1,009	1,541	1,711	477	929
Financial royalty assets	587	614	691	738	784
Available for sale debt securities	70	66	1	18	58
Other royalty income receivable	6	15	20	22	27
Other current assets	9	7	91	4	4
Total current assets	2,697	2,878	2,555	1,274	1,802
Financial royalty assets, net	12,368	13,718	13,493	14,089	15,127
Equity securities	299	270	112	199	187
Available for sale debt securities	144	204	226	437	694
Equity method investments	455	435	397	376	379
Other assets	23	4	30	7	34
Total assets	16,020	17,516	16,813	16,382	18,223
Distributions payable to legacy non-controlling interests	-	-	-	83	76
Accounts payable and accrued expenses	11	6	8	15	13
Interest payable	42	58	54	52	98
Current portion of long-term debt	-	-	998	-	998
Other current liabilities	-	-	12	11	69
Total current liabilities	308	171	1,167	161	1,254
Long-term debt	5,817	7,096	6,119	6,135	6,615
Other liabilities	-	-	3	1	12
Total liabilities	6,124	7,267	7,288	6,298	7,880
Class A Ordinary Shares	0	0	0	0	0
Class R Redeemable Shares	0	0	0	0	0
Additional paid-in capital	2,866	3,508	3,666	4,011	4,103
Retained earnings	1,921	2,255	1,965	2,518	2,846
Non-controlling interests	5,077	4,472	3,897	3,558	3,396
Treasury interests	2	3	3	3	3
Class A Ordinary Shares	0	0	0	0	0
Class R Redeemable Shares	0	0	0	0	0
Total shareholders’ equity	9,896	10,249	9,525	10,084	10,342
Total liabilities and shareholders’ equity	16,020	17,516	16,813	16,382	18,223